5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one

• ChemBase ID: 4791
• Molecular Formular: C19H9Cl2F2N3OS
• Molecular Mass: 436.2620664
• Monoisotopic Mass: 434.98114472
• SMILES: Fc1ccc(Sc2ccc3c(c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1
• Canonical SMILES: Fc1ccc(c(c1)F)Sc1ccc2n(n1)cnc(=O)c2c1c(Cl)cccc1Cl
• InChI: InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H
• InChIKey: VEPKQEUBKLEPRA-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one
• IUPAC Traditional name: 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]pyrimido[1,6-b]pyridazin-6-one
• Synonyms: 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-Dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-6H-pyrimido[1,6-b]pyridazin-6-one; VX 745; VX-745

Database IDs

• CAS Number: 209410-46-8
• PubChem SID: 160968223; 99443609
• PubChem CID: 3038525

CALCULATED PROPERTIES

JChem

• H Acceptors: 4
• H Donor: 0
• LogD (pH = 5.5): 4.8862553
• LogD (pH = 7.4): 4.8862553
• Log P: 4.8862553
• Molar Refractivity: 108.1496 cm^3
• Polarizability: 39.890594 Å^3
• Polar Surface Area: 45.03 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 5.17
• LOG S: -5.89
• Solubility (Water): 5.59e-04 g/l

PROPERTIES

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: p38 MAPK

Product Information

• Salt Data: Free Base

DETAILS

DrugBank - DB07138

Drug information: experimental

Selleck Chemicals - S1458

Research Area

• Description: Cancer

Biological Activity

• Description: VX-745 is a potent and selective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nM and 220 nM, respectively.
• Targets: p38α MAPK; p38β MAPK
• IC50: 10 nM ^[1]; 220 nM ^[1]
• In Vitro: VX-745 selectively inhibits p38α and p38β MAPK with IC50 of 10 nM and 220 nM, respectively, but not p38γ MAPK and a large panel of other kinases, with IC50 larger than 20 μM. In a human peripheral blood mononuclear cell (PBMC) assay, VX-745 provides IC50 of 56 and 52 nM for IL-1β and TNFα, respectively. VX-745 blocks IL-6 and IL-8 production induced by IL-1 and TNFα, and COX-2 synthesis mediated by LPS and IL-1β. ^[1-3]VX-745 (60 nM–20 μM) inhibits IL-6 and VEGF secretion in bone marrow stromal cells (BMSCs), without affecting their viability. VX-745 also inhibits TNF-α–induced IL-6 secretion in BMSCs. VX-745 inhibits both multiple myeloma (MM) cell proliferation and IL-6 secretion in BMSCs triggered by adherence of MM cells to BMSCs, suggesting that VX-745 can inhibit paracrine multiple myeloma (MM) cell growth in the BM milieu and overcome cell adhesion-related drug resistance. ^[4]
• In Vivo: VX-745 is effective against adjuvant-induced arthritis (AA) in the rat with ED50 of 5 mg/kg. Histological scores for VX-745 in AA rats are 93% inhibition of bone resorption and 56% inhibition of inflammation. In the classical cartilage-induced arthritis model, VX-745 exhibits a dose-responsive decrease in severity score. ^[1-3]In a type II collagen-induced arthritis (CIA) mice model, VX-745 (2.5, 5, and 10 mg/kg) has 27%, 31%, and 44% improvement in the inflammatory scores, respectively, when compared to vehicle-treated mice. In addition, histological scores show a 32–39% protection of bone and cartilage erosion by VX-745. ^[5]
• Features: VX-745 is a potent and selective inhibitor to p38α and p38β MAPK.

Protocol

• Protocol: Kinase Assay ^[5]
• Spectrophotometric coupled-enzyme assay: The IC50 for the inhibition of p38α and p38β homologs are obtained by a spectrophotometric coupled-enzyme assay. A fixed concentration of enzyme (15 nM of p38α or p38β) is incubated with VX-745 in DMSO for 10 min. at 30 °C in 0.1 M HEPES buffer, pH 7.5, containing 10% glycerol, 10 mM MgCl₂, 2.5 mM phosphoenolpyruvate, 200 μM NADH, 150 μg/mL pyruvate kinase, 50 μg/mL lactate dehydrogenase, and 200 μM EGF receptor peptide (KRELVEPLTPSGEAPNQALLR). The reaction is initiated with 100 μM and 70 μM ATP for p38α and p38β assays, respectively. The decrease of absorbance at 340 nm is monitored to follow the rate of the reaction. IC50 is evaluated from the rate data as a function of the inhibitor concentration.
• Protocol: Cell Assay ^[4]
• Cell Lines: Human bone marrow stromal cells (BMSCs) and multiple myeloma (MM) cells
• Concentrations: 60 nM - 20 μM, dissolved in DMSO.
• Incubation Time: 48 hours
• Methods: BMSCs (5 × 10^4 cells/well) or MM cells (3 × 10^4 cells/well) are incubated in 96-well culture plates in the presence or absence of VX-745 for 48 hours at 37 °C. DNA synthesis is measured by [^3H]-thymidine ([^3H]TdR) uptake. Cells are pulsed with [^3H]TdR (0.5 μCi/well [.0185 MBq]) during the last 8 hours of 48-hour cultures. Growth inhibition of both MM cells and BMSCs by VX-745 is also assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) dye absorbance.
• Protocol: Animal Study ^[5]
• Animal Models: Type II collagen-induced arthritis (CIA) mice model (DBA/1J)
• Formulation: Dissolved in 100% polyethylene glycol
• Doses: 2.5, 5, and 10 mg/kg
• Administration: Oral gavage twice daily

References

• References: [1] Decicco C, et al. American Chemical Society, 2000, May 15-17.
• References: [2] Haddad JJ, Curr Opin Investig Drugs, 2001, 2(8), 1070-1076.
• References: [3] Salituro FG, et al. 27th National Medicinal Chemistry Symposium, 2000, June 16.
• References: [4] Hideshima T, et al. Blood, 2003, 101(2), 703-705.
• References: [5] Duffy JP, et al. ACS Med Chem Lett, 2011, 2(10), 758-763.

Toronto Research Chemicals - V900500

VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.

REFERENCES

• Haddad, J.J.: Curr. Opin. Invest. Drugs, 2, 1070 (2001)
• Duffy, J.P. et al.: ACS Med. Chem. Lett., 2, 758 (2001)
• Bagley, M.C. et al.: Pharmaceuticals, 3, 1842 (2001)